Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Reported annual fiscal-period values; no daily interpolation.
PEG RATIO
N/A
PEG RATIO AVG TTM
1.85
PEG RATIO AVG 3Y
3.49
PEG RATIO AVG 5Y
3.16
PEG RATIO AVG 10Y
2.72
PEG RATIO AVG 15Y
2.30
PEG RATIO AVG 20Y
1.58
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alnylam Pharmaceuticals, Inc.
Market Cap
$31.73B
PEG Ratio
N/A
TTM Avg
1.85
3Y Avg
3.49
5Y Avg
3.16
Market Cap
$32.40B
PEG Ratio
4.14
TTM Avg
2.27
3Y Avg
2.27
5Y Avg
1.52
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.73B | N/A | 1.85 | 3.49 | 3.16 |
| Centene Corp. (CNC)vs › | $31.99B | N/A | 0.18 | 0.16 | 0.16 |
| Biogen Inc. (BIIB)vs › | $32.28B | N/A | 0.34 | 0.24 | 0.23 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.40B | 4.14 | 2.27 | 2.27 | 1.52 |
| Zoetis Inc. (ZTS)vs › | $32.42B | 2.04 | 2.96 | 3.83 | 3.78 |
| Waters Corporation (WAT)vs › | $31.02B | 75.61 | 75.61 | 40.77 | 27.51 |
| Medline Inc. (MDLN)vs › | $29.83B | N/A | 0.07 | 0.07 | 0.07 |
| DexCom, Inc. (DXCM)vs › | $34.27B | 0.67 | 19.51 | 10.66 | 8.56 |
| ResMed Inc. (RMD)vs › | $34.86B | 2.00 | 1.36 | 1.79 | 1.56 |
| Alcon Inc. (ALC)vs › | $35.12B | N/A | 5.21 | 5.21 | 4.55 |
PEG Ratio
N/A
P/E Ratio
40.0
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 2.84 |
| 2023-12-31 | 0.87 |
| 2021-12-31 | 6.76 |
| 2020-12-31 | 2.17 |
| 2015-12-31 | 0.95 |
| 2013-12-31 | 1.42 |
| 2010-12-31 | 1.08 |
| 2008-12-31 | 0.54 |
| 2006-12-31 | 0.44 |
| 2005-12-31 | 0.24 |
| 2004-12-31 | 0.03 |
